Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (alveolar cells type 2) | 0.10 |
| chemistry Open Targets | compounds already reach it: bococizumab, lerodalcibep, ongericimab +7 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 14 Parkinson's papers of 7,680 | 0.64 |
| pathways Reactome | 4 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 4081
Sealed predictions
- PCSK9 in dopamine neurons, braak+0.08 (p 0.838) → -0.77 (p 0.015)receipt 4089
Swarm cases
receipt 4089: PCSK9 in dopamine neurons, braak
- power
- full sample -0.21 (p 0.408, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.25 (p 0.310, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.140, n 18). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.11, sign flips 0; without severely affected donors -0.21 (p 0.408, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PCSK9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts